8-K
filed February 1, 2024, 6:59 PM ET
CIK 0000316253
leadership
confidence high
sentiment neutral
materiality 0.65
Enzo Biochem names permanent CEO and CFO; shareholders reject say-on-pay
ENZO BIOCHEM INC
- Kara Cannon appointed permanent CEO (was interim since Sept 2023); Patricia Eckert appointed permanent CFO.
- Shareholders elected directors Pully, Radoff, Tagliaferri, Cannon; Radoff and Tagliaferri had narrow margins.
- Non-binding advisory vote on executive compensation rejected: 13.9M for vs 17.3M against.
- Shareholders ratified EisnerAmper as independent auditor for FY2024 ending July 31, 2024.
- 44.4M shares (87.94%) represented at meeting; quorum present.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kara Cannon was appointed as Chief Executive Officer at ENZO BIOCHEM INC.
- Action
- appointed
- Role
- Chief Executive Officer
Exact text from the filing
On January 31, 2024, the board of directors (the “Board”) of Enzo Biochem, Inc. (the “Company”) appointed Kara Cannon to serve as the Chief Executive Officer of the Company and Patricia Eckert, CPA, to serve as the Chief Financial Officer of the Company, in each case, until her successor is duly elected and qualified.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Patricia Eckert was appointed as Chief Financial Officer at ENZO BIOCHEM INC.
- Action
- appointed
- Role
- Chief Financial Officer
Exact text from the filing
On January 31, 2024, the board of directors (the “Board”) of Enzo Biochem, Inc. (the “Company”) appointed Kara Cannon to serve as the Chief Executive Officer of the Company and Patricia Eckert, CPA, to serve as the Chief Financial Officer of the Company, in each case, until her successor is duly elected and qualified.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ENZO BIOCHEM INC shareholders rejected Approval, by a nonbinding advisory vote, of the compensation of the Company's named executive officers.
- Proposal
- say on pay
- Outcome
- failed
Exact text from the filing
The shareholders of the Company did not approve, by a nonbinding advisory vote, the compensation of the Company's named executive officers, as set forth below.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ENZO BIOCHEM INC shareholders approved Ratification of the Company's appointment of EisnerAmper LLP to serve as the Company's independent registered public accounting firm for the fiscal year ending July 31, 2024 at the 2024-07-31 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2024-07-31
Exact text from the filing
The shareholders of the Company ratified the Company's appointment of EisnerAmper LLP to serve as the Company's independent registered public accounting firm for the Company's fiscal year ending July 31, 2024, as set forth below.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ENZO BIOCHEM INC shareholders approved Election of Steven J. Pully, Bradley L. Radoff, Mary Tagliaferri, M.D., and Kara Cannon to the Board.
- Proposal
- director election
- Outcome
- passed
Exact text from the filing
The shareholders of the Company elected each of Steven J. Pully, Bradley L. Radoff, Mary Tagliaferri, M.D., and Kara Cannon to serve on the Board for a term ending as of the Company's 2024 Annual Meeting of Shareholders, and until each such director's successor is elected and qualified, as set forth below.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.